DSM has announced that the company has partnered with BiO2 Medical to provide DSM’s proprietary ComfortCoat lubricious coating and its coating application expertise for use in BiO2 Medical’s Angel catheter.
Placed at a patient’s bedside, the Angel catheter is intended to provide inferior vena cava filter protection from pulmonary embolism immediately following admission to the intensive care unit, while simultaneously allowing for central venous access in critically ill patients.
The unique design of the Angel catheter incorporates the pulmonary embolism protection of a retrievable, nitinol inferior vena cava filter, permanently attached to a triple lumen, central venous access catheter. The Angel Catheter is the first inferior vena cava filter to receive CE mark approval for a prophylactic use indication, in addition to traditional inferior vena cava filter and central venous catheter indications.
“This partnership allows our flagship product, the Angel catheter, to be easily placed at the patient’s bedside by the attending physician due to DSM’s hydrophilic and lubricous coating technology,” said Jeff Steinmetz, vice president of Research & Development, BiO2 Medical. “We partnered with DSM due to their highly regarded technical support, responsiveness, and ability to meet project timelines.”
“The Angel catheter’s hydrophilic coating makes it easy to place and may reduce vessel site trauma, which is important for my critically ill patients,” said Carl Waldmann, consultant anaesthetist and intensive care, Royal Berkshire NHS Trust, Reading, UK.
“DSM’s proprietary coating technologies and coating processes have a wide range of applications, making them suitable for devices across many medical competences,” said Hinke Malda, director of Coatings, DSM Biomedical. “We are proud to see our ComfortCoat coating contributing to the performance of BiO2Medical’s Angel catheter. The usage in this new catheter not only demonstrates the broad capabilities of our technologies but also underscores how committed DSM and its partners are to addressing unmet market needs with medical innovations.”
The Angel catheter has CE mark approval and is currently commercialised in Europe and the Middle East. It is also the subject of an FDA Early Feasibility Pilot Study Program. Up to 10 patients will be enrolled in the study with initial results anticipated to become available in Q2 of 2014.
